Theriva Biologics (TOVX) Net Income towards Common Stockholders (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Net Income towards Common Stockholders of -$2.0 million for Q1 2026, up 52.73% year-over-year from -$1.3 million in Q1 2025, and up 42.41% quarter-over-quarter from -$3.5 million in Q4 2025.
Theriva Biologics (TOVX) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Net Income towards Common Stockholders for 16 consecutive years, with -$2.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 52.73% year-over-year to -$2.0 million; the TTM figure through Mar 2026 stood at -$23.1 million (up 6.83% YoY), while the FY2025 annual figure was -$25.2 million, up 1.57% from the prior year.
- Net Income towards Common Stockholders climbed to -$2.0 million in Q1 2026 per TOVX's latest filing, from -$3.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$2.0 million in Q1 2026 and bottomed at -$13.1 million in Q2 2025.
- Historically, Net Income towards Common Stockholders has averaged -$5.4 million across 5 years, with a median of -$4.5 million in 2023.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 62.71% — and 2024, when it slumped 133.33%.
- Theriva Biologics' Net Income towards Common Stockholders stood at -$6.4 million in 2022, then climbed by 15.19% to -$5.4 million in 2023, then climbed by 18.39% to -$4.4 million in 2024, then rose by 20.19% to -$3.5 million in 2025, then soared by 42.41% to -$2.0 million in 2026.
- Business Quant data shows TOVX's Net Income towards Common Stockholders at -$2.0 million in Q1 2026, -$3.5 million in Q4 2025, and -$4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | -3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.22 Mn |
| Mar 31, 2026 | -2.04 Mn |
| Dec 31, 2025 | -3.55 Mn |
| Sep 30, 2025 | -4.40 Mn |
| Jun 30, 2025 | -13.10 Mn |
| Mar 31, 2025 | -4.32 Mn |
| Dec 31, 2024 | -4.45 Mn |
| Sep 30, 2024 | -7.70 Mn |
| Jun 30, 2024 | -8.32 Mn |
| Mar 31, 2024 | -5.20 Mn |
| Dec 31, 2023 | -5.45 Mn |
| Sep 30, 2023 | -3.30 Mn |
| Jun 30, 2023 | -5.10 Mn |
| Mar 31, 2023 | -4.48 Mn |
| Dec 31, 2022 | -6.43 Mn |
| Sep 30, 2022 | -4.83 Mn |
| Jun 30, 2022 | -4.48 Mn |
| Mar 31, 2022 | -4.27 Mn |
| Dec 31, 2021 | -5.29 Mn |
| Sep 30, 2021 | -3.30 Mn |